Your browser doesn't support javascript.
loading
All-in-one biofabrication and loading of recombinant vaults in human cells.
Martín, Fernando; Carreño, Aida; Mendoza, Rosa; Caruana, Pablo; Rodriguez, Francisco; Bravo, Marlon; Benito, Antoni; Ferrer-Miralles, Neus; Céspedes, M Virtudes; Corchero, José Luis.
Affiliation
  • Martín F; Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
  • Carreño A; Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
  • Mendoza R; Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
  • Caruana P; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain.
  • Rodriguez F; Grup d´Oncologia Ginecològica i Peritoneal. Institut d'Investigacions Biomédiques Sant Pau, Hospital de Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Bravo M; Grup d´Oncologia Ginecològica i Peritoneal. Institut d'Investigacions Biomédiques Sant Pau, Hospital de Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Benito A; Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Universitat de Girona, 17003 Girona, Spain.
  • Ferrer-Miralles N; Institut d'Investigació Biomèdica de Girona Josep Trueta, (IdIBGi), 17190 Salt, Spain.
  • Céspedes MV; Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Universitat de Girona, 17003 Girona, Spain.
  • Corchero JL; Institut d'Investigació Biomèdica de Girona Josep Trueta, (IdIBGi), 17190 Salt, Spain.
Biofabrication ; 14(2)2022 03 09.
Article in En | MEDLINE | ID: mdl-35203066
One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features,in vitrostability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles Limits: Humans Language: En Journal: Biofabrication Journal subject: BIOTECNOLOGIA Year: 2022 Document type: Article Affiliation country: Spain Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles Limits: Humans Language: En Journal: Biofabrication Journal subject: BIOTECNOLOGIA Year: 2022 Document type: Article Affiliation country: Spain Country of publication: United kingdom